Introduction
Chronic graft-versus-host disease (cGVHD) remains the most common late complication of allogeneic stem cell transplantation (SCT) with reported incidences ranging from 30% to 80% 1 . Despite improvements in the prevention of acute GVHD, only T-cell depletion 2 has resulted in a concomitant decrease in the incidence of cGVHD. The high incidence of chronic GVHD partly relates to the increase in the fraction of patients surviving transplant complications as well as the recent changes in clinical SCT methods. SCT using donors other than HLA-identical siblings and, recently, the use of blood as a source of hematopoietic stem cells are increasing 3 . Donor lymphocyte infusion whether given after non-myeloablative SCT or for relapse is also reported to be associated with severe acute and chronic GVHD and sometimes with unusual GVHD presentations. 4 Although cGVHD may have beneficial graft-versus-leukemia/lymphoma effects, large, observational studies identify cGVHD as the leading cause of non-relapse deaths occurring more than 2 years post transplant. 5 Mortality related to cGVHD is largely attributable to infectious complications and organ failures.
While more basic research is needed to better understand the pathogenesis of this entity, new treatment strategies that optimize currently available therapies are also needed to improve the outcome of cGVHD.
Approximately 40% of patients do not respond to initial therapy. 6, 7 Other studies show that some patients are over diagnosed and over treated. 8 Response rates to prednisone, azathioprine, cyclosporine or combination regimens varied considerably among clinical trials 9, 10 implying patient selection plays an important role in treatment outcome. 11 Identifying patients most likely to have a poor outcome with cGVHD may allow intensification of prophylaxis and/or therapy for high-risk patients and avoid unnecessary immune suppression in others. In the absence of a reliable stratification system, it is also difficult to conduct rigorous clinical trials. Determining prognostic factors for survival in patients with cGVHD would be a valuable tool in interpreting results of clinical trials with new agents.
However, the definition of risk status in patients with cGVHD is controversial. Although highly reproducible among transplant centers 12 the current grading system of limited versus extensive cGVHD, originally proposed in 1980 based on the clinicopathologic findings of 20 patients 13 has limitations. It only divides patients into those needing treatment (extensive cGVHD) and those who do not (limited cGVHD). The significant proportion of patients falls into the extensive cGVHD category and there is great heterogeneity in manifestations of cGVHD and patient outcomes within this group. Limitations of this classification system become more apparent as the incidence of cGVHD and the need for conducting randomized clinical trials increases.
For personal use only. on . by guest www.bloodjournal.org From 4 Despite growing interest in developing models to predict the risk of dying in patients with cGVHD, it has been extremely difficult to devise a more helpful grading system. Several clinical features have had prognostic significance in previous studies, including "extensive" cGVHD 9, 13 (multi-organ or extensive cutaneous involvement), Karnofsky performance status 9 , thrombocytopenia (less than 100,000 cells/µL) 16 and subjective measures of severity. 17 Because of limitations in the numbers of subjects studied, heterogeneity of patient populations, and variations in diagnosis and management of cGVHD, no prognostic factors except for thrombocytopenia and progressive-type onset have been reproduced by other investigators.
Consequently, there has been no consensus about the best grading system for cGVHD. Risk stratification by platelet count has been validated by Przpiorka and her colleagues 18 . In their data set, the long-term progression-free survival was 31% for patients without chronic GVHD, 51% for patients with low-risk (not thrombocytopenic), and 16% for patients with high-risk (thrombocytopenic) chronic GVHD.
We recently developed a prognostic model for cGVHD-specific survival by analyzing data on 151
consecutive patients who underwent allogeneic SCT at Johns Hopkins Oncology Center and subsequently were diagnosed with cGVHD 19 . We studied the relationship between pretreatment clinical and laboratory features and cGVHD-specific survival (survival without recurrent malignancy). First, we examined these variables individually. Then we created a multivariable model using a stepwise modeling approach based on proportional hazards regression. We confirmed that thrombocytopenia (TP) and progressive-type onset (PTO) were independent risk factors at diagnosis of cGVHD for shortened survival. We also identified extensive skin GVHD (ESI) involving greater than 50% of body surface area (BSA) as another independent risk factor (RF) affecting the survival. A composite prognostic factor score (PS) was calculated for each patient by adding together the weighted averages of each of the RFs (weighted by the estimated regression coefficient). Then, patients were stratified into different prognostic groups based on their total scores. This prognostic model constituted the basis of the proposed new grading system in cGVHD. This report describes the performance of this new prognostic scoring model and the individual RFs in four external data sets from different institutions.
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Materials and Methods
Five comprehensive transplant centers and the International Bone Marrow Transplant Registry (IBMTR) were asked to participate in this multi-center project in cGVHD. Two centers declined participation.
University of Nebraska Medical Center (UN), IBMTR, Fred-Hutchinson Cancer Research Center (FHCRC), and University of Minnesota (UM) contributed survival data from a total of 1105 cGVHD patients with complete clinical and follow-up information. All participating centers were asked to create a separate data set in which the model could be tested independently. Risk factor data for each patient at the time of initial diagnosis of cGVHD (or at the time of first reporting to the IBMTR) were considered. Date of death, the last follow-up date, and cause of death were included. Data were collected by all centers by reviewing the patient forms, abstracts or medical records using standard procedures after obtaining an approval from the institutional review boards.
The extent of skin involvement in FHCRC patients was retrieved retrospectively from patients' abstracts using the Rule of 9's burn scale, which is similar to the method used at Hopkins. The data on skin GVHD were available in the other data sets but the extent of involvement was either described differently (IBMTR) or was missing (UN and UM). In the IBMTR data collection forms, skin involvement had been originally coded as "mild", "moderate", and "severe". Therefore, these data were re-coded as equal or less than 50% BSA if it was originally recorded as "mild skin GVHD" and greater than 50% if it was "moderate or severe skin GVHD". The effect of this classification system versus one in which, only "severe" involvement was considered greater than 50% was then tested in sensitivity analysis. In the UN and UM cohorts, the extent of skin involvement was considered greater than 50% if cGVHD was originally classified as "extensive" cGVHD with skin involvement and equal or less than 50% for those who had "limited" cGVHD with skin involvement.
Following the creation of the database, a prognostic score (PS) for each patient was calculated as described in the original study. 19 The follow-up data in the learning sample was updated as of April 2002 and regression coefficients (weighted averages) of the prognostic factors were recalculated before testing the model and the individual risk factors in these external data sets. The coefficients by which they are multiplied were 1.949 for ESI, 1.293 for TP, and 0.514 for PTO. PS for any given patient was derived by adding together the products of the coefficient of each of the three significant risk factors at the time of diagnosis multiplied the value of the factor (0 if that absent, 1 if present). 
Results

Learning (training) sample
A total of 151 patients with a median age of 33 years (range 4 to 62) had been included in the original study. 19 Patient characteristics are summarized in Table 1 . Twenty-three patients (16%) were under the age of 21 years old. One hundred forty patients (93%) received SCT from an HLA-identical donor. Fifty-three percent of patients had their transplants before 1990. Onset of cGVHD was a median of 129 days (27 to 1026) after SCT. Fifty-three patients (35%) had progressive-type onset of cGVHD. Forty-five percent of patients had extensive skin involvement. Platelet count was less than 100.000 cells/µL in 71 (47%) patients.
As of April 2002, the median follow-up for surviving patients was 8.3 years. The probability of cGVHDspecific survival at 3 years after the diagnosis of cGVHD was 58% (95%CI, 49%, 65%) ( Figure 1A ). At the time of analysis, 67 patients (44%) were expired due to causes other than relapse of underlying hematologic malignancies. Fifty-eight patients (87%) died from various infectious complications during the course of cGVHD. Seventeen of 151 patients (11%) died from relapse of underlying malignancies.
According to univariate analysis, extensive skin GVHD involving > 50% of BSA (ESI), poor performance status (KPS < 80%), thrombocytopenia (TP) ( less than100,000 cells/µL), progressive-type onset (PTO), date of transplant, low absolute serum immunoglobulin G level (<500 mg/dl), hyperbilirubinemia (greater than 1.2 mg/dl), and presentation with a systemic infection at the diagnosis of cGVHD were significant risk factors for shortened survival. Multivariable analysis demonstrated that ESI, TP, and PTO were independently associated with shortened survival with respective hazard ratios of 7.0, 3.6, and 1.7. The probability of survival at 3 years for 54 patients with PS 0 (favorable-risk group; 0 RF) was 92% (95% CI, 80%, 97%). Forty-seven patients with PS between 0 and 2 (intermediate-risk group; 1 RF) had 71% (95% CI, 55%, 82%) and 50 patients with PS equal or greater than 2 (high-risk group; more than 1 RF) had 9% (95% CI, 3%, 19%) probability of survival at 3 years ( Figure 1B 
Test Samples
Baseline clinical and laboratory characteristics at the time of diagnosis of cGVHD of the learning and test samples are summarized in Table 1 . The distribution of the three independent RFs in test samples and the number of patients in each of these three prognostic subgroups are summarized in Table 2 Table 3) . The 3-year probabilities of cGVHD-specific survival for 23 (38%), 30 (50%), and 7 (12%) patients in favorable-, intermediate-, and high-risk groups were 77% (95% CI, 53%, 90%), 42% (95% CI, 24%, 59%) and 14% (95% CI, 0.7%, 46%) respectively ( Figure 2B ). Of note, two patients in the favorable risk group died at 6 and 6.5 years without evidence of active chronic GVHD. Thrombocytopenia was the only significant predictor of survival after adjusting for the other two RFs (Table 4) .
Cohort 2:
The IBMTR data included 708 patients with a median age of 35 years (range 16 to 60) who underwent allogeneic bone marrow transplantation from an HLA-identical sibling donor between 1990 and 1994 at 119 centers with data on 1 to 52 patients per center. Chronic GVHD was diagnosed in a median of 134 days (range 60-1025 days) after transplantation. Twenty-two percent of patients presented with progressive-type cGVHD. Twenty-six percent of patients had extensive skin GVHD and 37% had thrombocytopenia at the time of diagnosis of cGVHD or initial reporting to the IBMTR. Median follow-up for surviving patients after diagnosis of cGVHD was 1.2 years and the 3-year probability of cGVHD-specific survival for the entire group was 77% (95% CI, 72%, 81%) ( Figure 3A) . The HR for comparison of the intermediate-risk to the favorable-risk group was 3.3 and the HR for comparison of the high-risk to the intermediate-risk group was 2.5 ( Table 3) . The 3-year probabilities of cGVHD-specific survival for 314 (44%), 282 (40%), and 112 (16%) patients in favorable-, intermediate-, and high-risk groups were 91% (95% CI, 85%, 95%), 74% (95% CI, 66%, 80%) and 49% (95% CI, 37%, 60%), respectively ( Figure 3B ). In this cohort, extensive skin involvement was the strongest predictor of survival after adjusting for the other two risk factors. The HR comparison of ESI (moderate/severe skin GVHD, coded as greater than 50% BSA) to
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From 9 non-ESI (mild/no skin GVHD, coded as equal or less than 50% BSA) was 3.3 after adjusting for TP and PTO (Table 4) . TP and PTO were also significant risk factors for survival in this cohort.
The analysis was then repeated reclassifying only "severe" skin GVHD as ESI. However, this reduced the proportion of the IBMTR population with ESI to 7% (compared to 22-72% in the other cohorts). ESI still remained an independent predictor for poor survival after adjusting for the other two risk factors. The HR comparison of ESI (severe skin GVHD, coded as >50% BSA) to non-ESI (none, mild and moderate skin GVHD, coded as <50% BSA) was 2.0 after adjusting for TP and PTO (p=0.01). of 188 patients (8%) had all 3 risk factors at diagnosis of cGVHD (Table 2) . Median follow-up for 157 surviving patients after diagnosis of cGVHD was 1.6 years, ranging from 0.1 to 5.1 years. The 3-year probability of cGVHD-specific survival for the entire group was 77% (95% CI, 69%, 84%) ( Figure 4A ). The 3-year probabilities of cGVHD-specific survival for 42 (22%), 108 (58%), and 38 (20%) patients in favorable-, intermediate-, and high-risk groups were 96% (95% CI, 76%, 99%), 77% (95% CI, 65%, 85%) and 62% (95% CI, 42%, 77%), respectively ( Figure 3B ). The HR for comparison of the intermediate-risk group to the favorable-risk group was 8.9 and the HR for comparison of the high-risk group to the intermediate-risk group was 1.6 (Table 3) . Thrombocytopenia was the only significant predictor of survival after adjusting for the other two risk factors (Table 4) . 
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MTX and prednisone. The median time from transplant to onset of cGVHD was 141 days (range 52 to 775 days). Forty-six percent had progressive onset and 72% had extensive skin cGVHD. Fifty-nine percent of patients had thrombocytopenia. This cohort had the highest percentage (63%) of patients with at least 2 risk factors at diagnosis of cGVHD (Table 2) . For the entire group, the probability of cGVHD-specific survival at 3 years after the diagnosis of cGVHD was 54%, (95% CI, 45%, 62%) ( Figure 5A ). The 3-year probabilities of survival for 17 (11%), 47 (32%), and 85 (57%) patients in favorable-, intermediate-and highrisk groups were 81% (95% CI, 51%, 93%), 68% (95% CI, 52%, 80%), and 41% (95% CI, 30%, 52%), respectively ( Figure 5B (Table 3) . TP and PTO were independent predictors for survival after adjusting for the other risk factors (Table 4) 
Discussion
As in any other disease, one of the critical considerations in making a therapeutic decision for a patient with cGVHD is predicting the likely outcome. Accurate clinical grading or classification schemes may allow us to intelligently decide between earlier or more intensive immunosuppressive therapy for patients considered high-risk for cGVHD-related death versus less intensive approaches for those intrinsically destined to have a more favorable outcome. Therefore, classification of patients with cGVHD based on their prognosis is clinically more relevant than purely anatomic classification into limited versus extensive disease.
We previously identified three risk factors that are predictive for chronic GVHD-specific survival.
19
Excluding relapse-related deaths, four-level 19 or three-level 20 prognostic model based on these risk factors predicted the probability of being alive at 10 years ranging from 9% to 90%. The difference in this cGVHD-specific survival at 10 years was 30% between favorable-and intermediate-risk groups and 50% between intermediate-and high-risk groups. 20 Data set included many patients transplanted before 1990
and, as of April 2002, median follow-up was over 8 years. The primary assertion of the initial study was that consideration of skin involvement added significant prognostic information for predicting nonrelapse mortality among patients with newly diagnosed chronic GVHD.
Using multiple data sets that included a total of 1105 patients, we tested the validity of (1) prognostic scoring model and (2) each of the three prognostic factors that constituted this model. These cohorts represented heterogeneous patient populations with different sample sizes and distinct clinical characteristics that were treated in different institutions. The median survivals and the follow-ups, whether or not divided into prognostic subgroups were also not comparable among the cohorts. Differences in the date of transplant and date of diagnosis of chronic GVHD seems likely to be the major cause for discrepancies in survival outcome among these cohorts. Many of the patients in the learning sample were diagnosed with chronic GVHD before day+100, and some patients were transplanted in a pre-cyclosporine era.
The distribution of the risk factors among these groups was also not comparable possibly because of the variability in the method and timing of diagnosis of cGVHD as well as differences in the diagnostic criteria used for acute and chronic GVHD. One of the most difficult aspects of the management of chronic GVHD is making a timely diagnosis. Our previous data clearly indicates that making an accurate and early diagnosis is a critical step in the management of cGVHD 8 . In the learning sample, all but two patients had their cGVHD confirmed by biopsy. As mentioned earlier in the method section, FHCRC cohort was limited to patients diagnosed with cGVHD at the day +80 evaluation because of the availability of on-site skin evaluation.
Patients with early-onset cGVHD and those who had the diagnosis of extensive cGVHD outside this (Table 3 ). In the FHCRC cohort, while in the HRs comparing the favorable-risk group with the two other groups were statistically significant, the difference between intermediate-and highrisk groups did not reach to the conventional value of statistical significance despite different survival likelihoods. This might be due to limited power from the small number of high-risk patients.
In the original paper, the major new finding was the extremely high mortality hazard (7.0) associated with skin GVHD involving greater than 50% BSA. None of the test cohorts showed a similarly high mortality hazard associated with skin involvement greater than 50% BSA, and 3 of the 4 test cohorts showed no statistically significant association between the extent of skin involvement at the time of diagnosis and subsequent mortality after adjusting for TP and PTO. Reasons for the strikingly different hazard ratio estimates among different cohorts are not clear but might be related to selection criteria or methods for collecting this information. The generally similar hazard ratio estimates associated with thrombocytopenia and progressive-type of onset suggest that methods for measuring and reporting the extent of skin involvement were more important than patient selection in accounting for the lack of uniformity in hazard ratio estimates associated with skin involvement.
A possible limitation of the study was the absence of quantitative information about the extent of cGVHD skin involvement in the test samples except for cohort 3 (FHCRC). In order to estimate this information, the available data on skin GVHD was quantified using a predetermined criterion for each of these cohorts. This approach might have under or over estimated the actual extent of skin GVHD in some of these patients. To evaluate the effect of this bias, we applied the model in the same IBMTR data set after setting a cutoff between "moderate" and "severe" skin GVHD. When it was reclassified as having only "severe" skin GVHD, ESI remained a significant predictor of cGVHD-specific survival. Excluding patients who were originally coded as "moderate" skin GVHD from the analysis to eliminate the possible misclassification bias resulted in similar results. Thus, it is possible but not likely that our interpretation of ESI based on the For personal use only. on September 14, 2017. by guest www.bloodjournal.org From
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IBMTR categories of "mild, moderate, and severe" influenced conclusions in this data set. Regardless, the validity of the conclusion about the prognostic implication of the extensive skin GVHD may be limited by the contrived method of assessing skin involvement in data sets where this was not collected prospectively. Therefore, a prospective study using standardized criteria for organ involvement is needed to confirm the utility of the skin extent in this prognostic model.
The other explanation for the variable hazard ratio estimates associated with prognostic model in these data sets may be related to the study endpoint we used. As seen in the survival curves of UN, two patients in the favorable-risk group died at 6 and 6.5 years after cGVHD because of late events not related to GVHD or relapse. Chronic graft-versus-host disease is a unique syndrome. Relapse of underlying malignancy is the other major competing factor (10%) for death in patients with chronic GVHD 14, 18, 19 . We also observed that the probability of relapse was inversely correlated with the occurrence and severity 19 Despite its limitations, the new clinical grading or stratification system based on the PS model can be useful to individualize treatment plans in chronic GVHD. In a recent randomized study comparing single agent steroid with cyclosporine and steroid, the hazards of transplantation-related mortality, overall mortality, recurrent malignancy, secondary therapy, and discontinuation of all immunosuppressive therapy were not significantly different between the 2 arms, but survival without recurrent malignancy was lower in the 2-drug arm. 21 In lights of these new findings, it could be even more appropriate to treat patients in the favorable-risk category with corticosteroids alone. Alternatively, new treatment options other than corticosteroids may be sought in this group of patients. If patients fail to respond to steroids or other single agents, combination therapies might then be instituted. In contrast, patients with limited life expectancy due to poor-risk cGVHD may benefit from new therapeutic approaches. Clearly, the cGVHD-related mortality in this group is unacceptably high with current treatment approaches and new treatment paradigms are needed.
For
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In future prospective trials evaluating any new approaches to cGVHD therapy, patients should be stratified according to the new proposed clinical grading to insure a balanced distribution of risk factors among groups.
To improve comparability between publications, reports of cGVHD treatment trials should include an accurate description of the study population based on characteristics of the disease at the time of diagnosis.
In view of the limitations of the current grading system, this new clinical grading system could also be used to report severity of cGVHD instead of (or in addition to) the limited/extensive scale.
In conclusion, the prognostic model including the three risk factors (ESI, TP and PTO) is promising for clinical application because of its utility across multiple independent data sets. The utility of skin involvement must be validated prospectively before routinely including this characteristic as a risk factor for mortality. Until then, this clinical grading system could be used in its present form to improve clinical management by adjusting therapy, to group patients for clinical trials and to ensure better communication among the centers. (5) 16 (11) 86 (60) 42 (28) 0 (0) 1 (2) 32 (53) 27 (45) 0 55 (8) 411 (58) 242 (34) 18 (10) 26 (14) 66 (35) 78 (41) 25 (17) 24 (16) 68 (46) 32 (21 (20) 36 (60) 14 (23) 10 (17) 358 (51) 213 (30) 137 (19) 86 (46) 52 (28) 50 (27) 71 (48) 52 (35) 26 ( 59 (39) 69 (46) 13 (9) 6 (4) -17 (28) 22 (37) 10 (17) 11 (18) -304 (43) 404 (57) --2 (1) 63 (34) 76 (40) 20 (11) 27 (14) 16 (11) 40 (27) 59 (39) 4 (3) 30 (20)
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